Literature DB >> 9713630

Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages.

J E Losa García1, F Mateos Rodríguez, A Jiménez López, M J García Salgado, M R Martín de Cabo, J Pérez Losada, J L Pérez Arellano.   

Abstract

Cyclosporin A (CsA) is an immunomodulator drug that has been used in the treatment of several types of advanced pulmonary interstitial disease. This beneficial effect occurs mainly in circumstances in which alveolitis due to CD4 lymphocytes is absent, suggesting that CsA acts on other types of cells. The present study was undertaken to determine the effect of CsA on inflammatory cytokine secretion by human alveolar macrophages (AMs). Human AMs were collected by bronchoalveolar lavage from four control subjects and 13 patients with interstitial lung disease. Purified human AMs were incubated with different concentrations of CsA (200, 20 and 2 ng ml-1) in the presence or absence of lipopolysaccharide (LPS). Interleukin-1 beta (IL-1 beta), tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-8 levels were measured in supernatants using specific enzyme-linked immunosorbent assays. It was found that CsA inhibits basal secretion of TNF-alpha and IL-8 at 20 and 200 ng ml-1. However, none of the different concentrations of CsA modified basal secretion of IL-1 beta nor IL-6. By contrast, a lower concentration of CsA (2 ng ml-1) inhibits LPS-stimulated secretion of all inflammatory cytokines. It is concluded that CsA exerts a modest effect on inflammatory cytokine production by human AMs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713630     DOI: 10.1016/s0954-6111(98)90002-6

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.

Authors:  W Gao; P S Topham; J A King; S T Smiley; V Csizmadia; B Lu; C J Gerard; W W Hancock
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 2.  Bird fancier's lung: a state-of-the-art review.

Authors:  Andrew L Chan; Maya M Juarez; Kevin O Leslie; Heba A Ismail; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

3.  Cyclosporine A-Mediated IL-6 Expression Promotes Neural Induction in Pluripotent Stem Cells.

Authors:  Ashwathnarayan Ashwini; Sushma S Naganur; Bhaskar Smitha; Preethi Sheshadri; Jyothi Prasanna; Anujith Kumar
Journal:  Mol Neurobiol       Date:  2017-06-16       Impact factor: 5.590

Review 4.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Could intravenous cyclosporin A be an effective therapeutic strategy in pulmonary hemorrhage associated with Henoch-Schönlein purpura? Comment on: Pulmonary hemorrhage associated with Henoch-Schönlein purpura in a child [Clin Rheumatol 27(6):803-805].

Authors:  Jae Il Shin; Jae Seung Lee
Journal:  Clin Rheumatol       Date:  2008-08-21       Impact factor: 2.980

6.  Effect of FK506 (tacrolimus) in animal models of inflammation.

Authors:  Amanpreet Singh; Pattipati S Naidu; C S Patil; Shrinivas K Kulkarni
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

7.  Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells.

Authors:  J E Garcia; M R de Cabo; F M Rodríguez; J P Losada; A J López; J L Arellano
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

Review 8.  Phytochemicals as modulators of M1-M2 macrophages in inflammation.

Authors:  Uzma Saqib; Sutripta Sarkar; Kyoungho Suk; Owais Mohammad; Mirza S Baig; Rajkumar Savai
Journal:  Oncotarget       Date:  2018-04-03

9.  Management of hypersensivity pneumonitis.

Authors:  Ioana O Agache; Liliana Rogozea
Journal:  Clin Transl Allergy       Date:  2013-02-04       Impact factor: 5.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.